CeriBell (NASDAQ:CBLL) CRO Sells $24,804.00 in Stock

by · The Cerbat Gem

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CRO Joseph Manni sold 1,378 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $24,804.00. Following the completion of the sale, the executive directly owned 56,291 shares of the company’s stock, valued at $1,013,238. The trade was a 2.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Price Performance

NASDAQ:CBLL traded up $0.03 during midday trading on Tuesday, hitting $18.80. 187,155 shares of the stock were exchanged, compared to its average volume of 322,889. The company has a market capitalization of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The business has a 50-day moving average price of $19.08 and a two-hundred day moving average price of $19.19.

CeriBell (NASDAQ:CBLL – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. Sell-side analysts predict that CeriBell, Inc. will post -1.69 EPS for the current year.

Analyst Ratings Changes

CBLL has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Finally, Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average target price of $22.20.

Read Our Latest Report on CBLL

Institutional Trading of CeriBell

Several large investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its position in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the last quarter. Sei Investments Co. lifted its position in shares of CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG grew its holdings in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares during the last quarter. Finally, Strs Ohio bought a new position in CeriBell in the 1st quarter worth approximately $27,000.

About CeriBell

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

Featured Articles